Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objectives</h3><p>This study aimed to explore the novel biomarkers for immune checkpoint inhibitor (ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling, tumor mutational burden (TMB), and expression of programmed death receptor 1 ligand (PD‐L1).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Materials and Methods</h3><p>Tumor and blood samples from 637 Chinese patients with NSCLC were collected for targeted panel sequencing. Genomic alterations, including single nucleotide variations, insertions/deletions, copy number variations, and gene rearrangements, were assessed and TMB was computed. TMB‐high (TMB‐H) was defined as ≥10 mutations/Mb. PD‐L1 positivity was defined as ≥1% tumor cells with membranous staining. Genomic data and ICI outcomes of 240 patients with NSCLC were derived from cBioPortal.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p><i>EGFR</i>‐sensitizing mutations, <i>ALK</i>, <i>RET</i>, and <i>ROS1</i> rearrangements were associated with lower TMB and PD‐L1+/TMB‐H proportions, whereas <i>KRAS</i>, <i>ALK</i>, <i>RET</i>, and <i>ROS1</i> substitutions/indels correlated with higher TMB and PD‐L1+/TMB‐H proportions than wild‐type genotypes. Histone‐lysine N‐methyltransferase 2 (<i>KMT2</i>) family members (<i>KMT2A</i>, <i>KMT2C</i>, and <i>KMT2D</i>) were frequently mutated in NSCLC tumors, and these mutations were associated with higher TMB and PD‐L1 expression, as well as higher PD‐L1+/TMB‐H proportions. Specifically, patients with KMT2C mutations had higher TMB and PD‐L1+/TMB‐H proportions than wild‐type patients. The median progression‐free survival (PFS) was 5.47 months (95% CI 2.5–NA) in patients with KMT2C mutations versus 3.17 months (95% CI 2.6–4.27) in wild‐type patients (<i>p</i> = 0.058). Furthermore, in patients with NSCLC who underwent ICI treatment, patients with TP53/KMT2C co‐mutations had significantly longer PFS and greater durable clinical benefit (HR: 0.48, 95% CI: 0.24–0.94, <i>p</i> = 0.033). TP53 mutation combined with KMT2C or KRAS mutation was a better biomarker with expanded population benefit from ICIs therapy and increased the predictive power (HR: 0.46, 95% CI: 0.26–0.81, <i>p</i> = 0.007). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>We found that tumors with different alterations in actionable target genes had variable expression of PD‐L1 and TMB in NSCLC. TP53/KMT2C co‐mutation might serve as a predictive biomarker for ICI responses in NSCLC.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Implications for Practice</h3><p>Cancer immunotherapies, especially immune checkpoint inhibitors (ICIs), have revolutionized the treatment of non‐small cell lung cancer (NSCLC); however, only a proportion of patients derive durable responses to this treatment. Biomarkers with greater accuracy are highly needed. In total, 637 Chinese patients with NSCLC were analyzed using next‐generation sequencing and IHC to characterize the unique features of genomic alterations and TMB and PD‐L1 expression. Our study demonstrated that KMT2C/TP53 co‐mutation might be an accurate, cost‐effective, and reliable biomarker to predict responses to PD‐1 blockade therapy in NSCLC patients and that adding KRAS to the biomarker combination creates a more robust parameter to identify the best responders to ICI therapy.</p></section>

Association of KMT2C/D Loss-of-function Variants with Response to Immune Checkpoint Blockades in Colorectal Cancer

The Predictive Values of Loss-of-function Variants in Histone Methyltransferases for Response to Immune Checkpoint Inhibitors in Solid Tumors.

KMT2C As a Positive Predictor for Treatment of Immune Checkpoint Inhibitor and Correlation with Immune Infiltrates in Colorectal Cancer (CRC).

KRAS Mutation Subtypes Responded Differently to Combination Immunotherapy Via Disturbing Myeloid-Derived Suppressor Cells in Non-Small Cell Lung Cancer.

KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer

Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments

KMT2A/C Mutations Function As a Potential Predictive Biomarker for Immunotherapy in Solid Tumors

Pan‐cancer analysis on the role of KMT2C expression in tumor progression and immunotherapy

Effects of KMT2D Mutation and Its Exon 39 Mutation on the Immune Microenvironment and Drug Sensitivity in Colorectal Adenocarcinoma.

KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer

Low Mutation Burden and Differential Tumor-Infiltrating Immune Cells Correlate with Lymph Node Metastasis in Colorectal Cancer

Association of KMT2C loss-of-function mutations in circulating tumor DNA and prolonged response to the combination of PARPi and PI3Ki.

A Pan-Cancer Study of KMT2 Family As Therapeutic Targets in Cancer

Immune Profiling Of Microsatellite Instability-High And Polymerase Epsilon (Pole)-Mutated Metastatic Colorectal Tumors Identifies Predictors Of Response To Anti-Pd-1 Therapy

Effect of TP53 Mutation on Antitumor Immunity and Responsiveness to Immunotherapy in Colorectal Cancer.

Gene mutation profiling in microsatellite instability colorectal cancer and its association with the efficacy of immunotherapy: A retrospective study

Prognostic Impact Of Mutation Profiling In Chinese Patients With Colorectal Liver Metastases.

Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer

Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis

Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer

Systematic analysis the genomic and microenvironment characteristics with the status of human leukocyte antigen (HLA) and the integration of HLA LOH, TMB and PD-L1 could further distinguish the responders to immunotherapy.